Table 1.
Descriptive Analysis of Staging Procedures for Endometrial Cancer Among Gynecologic Oncologists, Stratified by Geographic Region
| Standard Practice of Staging for Endometrial Cancer | Overall (N=489)a | United States (n=118) | Europe (n=201) | Other Countries (n=117) |
|---|---|---|---|---|
| SLN Technique | ||||
| SLN technique used, No. (%) | 246 (50.3) | 82 (69.5) | 101 (50.2) | 42 (35.9) |
| Tracer most commonly injected, No. (%) | ||||
| Indocyanine green | 154 (62.6) | 72 (87.8) | 57 (56.4) | 12 (28.6) |
| Blue dye | 40 (16.3) | 3 (3.7) | 14 (13.9) | 19 (45.2) |
| Combination (indocyanine + blue) | 20 (8.1) | 6 (7.3) | 7 (6.9) | 6 (14.3) |
| Technetium Tc 99 | 4 (1.6) | 0 (0) | 4 (4.0) | 0 (0) |
| Technetium Tc 99 combined with other tracers | 24 (9.8) | 0 (0) | 19 (18.8) | 4 (9.5) |
| Other or item not answered | 4 (1.6) | 1 (1.2) | 0 (0) | 1 (2.4) |
| Site of injection, No. (%) | ||||
| Cervix | 229 (93.1) | 80 (97.6) | 91 (90.1) | 41 (97.6) |
| Uterine body | 3 (1.2) | 0 (0) | 2 (2.0) | 0 (0) |
| Cervix and uterine body | 10 (4.1) | 1 (1.2) | 7 (6.9) | 1 (2.4) |
| Other or item not answered | 4 (1.6) | 1 (1.2) | 1 (1.0) | 0 (0) |
| Backup lymphadenectomy after SLN biopsy performed, No. (%) | ||||
| In all cases | 37 (15.0) | 9 (11.0) | 18 (17.8) | 5 (11.9) |
| Only in “high risk” patients | 164 (66.7) | 52 (63.4) | 69 (68.3) | 30 (71.4) |
| Never | 40 (16.3) | 21 (25.6) | 12 (11.9) | 7 (16.7) |
| Item not answered | 5 (2.0) | 0 (0) | 2 (2.0) | 0 (0) |
| Pathologic evaluation of the SLNs removed, No. (%) | ||||
| Frozen section | 75 (30.5) | 23 (28.0) | 35 (34.7) | 12 (28.6) |
| Ultrastaging | 194 (78.9) | 69 (84.1) | 80 (79.2) | 33 (78.6) |
| Non-SLN Technique | ||||
| Non-SLN technique used, No. (%) | 243 (49.7) | 36 (30.5) | 100 (49.8) | 75 (64.1) |
| Reason for not adopting SLNb | ||||
| Not enough evidence | 122 (50.2) | 22 (61.1) | 61 (61.0) | 25 (33.3) |
| Lack of instrumentation | 110 (45.3) | 11 (30.6) | 37 (37.0) | 50 (66.7) |
| Cost | 30 (12.3) | 2 (5.6) | 9 (9.0) | 13 (17.3) |
| Standard practice for staging, No. (%) | ||||
| No lymph node assessment | 5 (2.1) | 0 (0) | 3 (3.0) | 0 (0) |
| Selective pelvic lymphadenectomy c | 26 (10.7) | 2 (5.6) | 8 (8.0) | 14 (18.7) |
| Systematic pelvic lymphadenectomy | 25 (10.3) | 0 (0) | 9 (9.0) | 14 (18.7) |
| Selective pelvic ± para-aortic lymphadenectomyc | 126 (51.9) | 25 (69.4) | 55 (55.0) | 29 (38.7) |
| Systematic pelvic + para-aortic lymphadenectomy | 52 (21.4) | 8 (22.2) | 22 (22.0) | 15 (20.0) |
| Other or not answered | 9 (3.7) | 1 (2.8) | 3 (3.0) | 3 (4.0) |
Abbreviations: SLN, sentinel lymph node; ±, with or without.
a
Geographic region was not reported by 53 respondents (10.8%).
b
Multiple answers were allowed.
c
Procedure was performed only if tumor-related risk factors for lymph node metastasis were present.